INOVIO PHARMACEUTICALS, INC. - 8-K Filing
Inovio Pharmaceuticals filed an 8-K on May 19, 2026, announcing amendments to its bylaws effective immediately, including clarifying the Chairman of the Board's role and establishing a Lead Independent Director position. The company also reported results from its annual stockholder meeting held on May 20, where eight directors were elected with majority votes ranging between 89% and 95%, Ernst & Young was ratified as auditors (with 96.7% approval), advisory compensation for executives received 84.3% support, and the amended 2023 Omnibus Incentive Plan passed with 84.1% approval. (Items: 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, 5.07 Submission of Matters to a Vote of Security Holders, 9.01 Financial Statements and Exhibits)
Tickers: $INO